CD133+ human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis
Article first published online: 17 NOV 2010
© 2010 The Authors. APMIS © 2010 APMIS
Volume 119, Issue 1, pages 66–75, January 2011
How to Cite
ELKHAFIF, N., EL BAZ, H., HAMMAM, O., HASSAN, S., SALAH, F., MANSOUR, W., MANSY, S., YEHIA, H., ZAKI, A. and MAGDY, R. (2011), CD133+ human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. APMIS, 119: 66–75. doi: 10.1111/j.1600-0463.2010.02693.x
- Issue published online: 9 DEC 2010
- Article first published online: 17 NOV 2010
- Received 31 March 2010. Accepted 13 October 2010
- CD133+ stem cells;
- experimental chronic hepatic fibrosis
Elkhafif N, El Baz H, Hammam O, Hassan S, Salah F, Mansour W, Mansy S, Yehia H, Zaki A, Magdy R. CD133+ human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. APMIS 2010.
The in vivo angiogenic potential of transplanted human umbilical cord blood (UCB) CD133+ stem cells in experimental chronic hepatic fibrosis induced by murine schistosomiasis was studied. Enriched cord blood-derived CD133+ cells were cultured in primary medium for 3 weeks. Twenty-two weeks post-Schistosomiasis infection in mice, after reaching the chronic hepatic fibrotic stage, transplantation of stem cells was performed and mice were sacrificed 3 weeks later. Histopathology and electron microscopy showed an increase in newly formed blood vessels and a decrease in the fibrosis known for this stage of the disease. By immunohistochemical analysis the newly formed blood vessels showed positive expression of the human-specific angiogenic markers CD31, CD34 and von Willebrand factor. Few hepatocyte-like polygonal cells showed positive expression of human vascular endothelial growth factor and inducible nitric oxide synthase. The transplanted CD133+ human stem cells primarily enhanced hepatic angiogenesis and neovascularization and contributed to repair in a paracrine manner by creating a permissive environment that enabled proliferation and survival of damaged cells rather than by direct differentiation to hepatocytes. A dual advantage of CD133+ cell therapy in hepatic disease is suggested based on its capability of hematopoietic and endothelial differentiation.